Risk of Metachronous Findings After Detection of Serrated Lesions and High-grade Dysplasia With Surveillance Delay

Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · Apr 27, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating how the presence of certain types of polyps, specifically serrated polyps and high-grade dysplasia, discovered during an initial colonoscopy, affects the risk of developing new high-risk adenomas (a type of abnormal growth) in patients over time. The goal is to better understand which patients may need closer monitoring after their first colonoscopy to prevent the progression of potential colorectal cancer.

To be eligible for this study, participants should be between 45 and 80 years old and have had a colonoscopy at the Montreal University Hospital Center from 2009 to 2022, where they were found to have one or more serrated lesions or high-grade dysplasia. Participants should not have certain conditions like inflammatory bowel disease or a hereditary syndrome that increases cancer risk. If you join this trial, you can expect to provide information about your colonoscopy experience, and your doctors will monitor your health closely to gather important data for this research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients 45-80 who underwent colonoscopy from 2009 to 2022 at the Montreal University Hospital Center (CHUM) with 1+ SL or HGD detected at index colonoscopy and lacking follow-up within or beyond the surveillance interval recommended by 2020 USMSTF guidelines.
• Exclusion Criteria:
• • 1) Patients with a diagnosis of inflammatory bowel disease;
• • 2) Hereditary CRC syndromes;
• • 3) CRC at index colonoscopy;
• • 4) Serrated polyposis syndrome;
• • 5) Life expectancy too short to benefit from colonoscopy;
• • 6) Follow-up colonoscopy not yet due according to USMSTF guidelines. Patients with concomitant HRA and SL at index will be invited to participate if the index (or last) colonoscopy was performed more than 1 year ago. This is based on the high rates of HRA we identified in our retrospective study posing increased risks for these patients.